J H Hesselvig1,2, A Egeberg1,2, K Kofoed1,2, G Gislason3, L Dreyer4,5,6,7. 1. Department of Dermatology and Allergy, Herlev and Gentofte University Hospital, Copenhagen, Denmark. 2. CORGIS - Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte University Hospital, Copenhagen, Denmark. 3. Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark. 4. Department of Rheumatology, Herlev and Gentofte University Hospital, Copenhagen, Denmark. 5. The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark. 6. Department of Clinical Medicine, Aalborg University and Aalborg University Hospital, Aalborg, Denmark. 7. Department of Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg, Denmark.
Abstract
BACKGROUND: There is a wide range in the reported prevalences of depression in patients with systemic lupus erythematosus (SLE), while the prevalence of depression in patients with cutaneous lupus erythematosus (CLE) remains severely understudied. OBJECTIVES: To examine whether patients with SLE or CLE have an increased risk of depression. METHODS: In this nationwide observational cohort study, we included patients aged ≥ 18 years with a first-time diagnosis of SLE or CLE between 2000 and 2015 identified in the Danish National Patient Register, which were matched with the general population in a ratio of 1 : 10. After linkage to national Danish health registers of primary and secondary care, analyses of risk for depression and antidepressant use were performed using Cox regression models adjusted for age, sex, socioeconomic status, smoking, alcohol abuse, prior depression and prior antidepressant use. RESULTS: A total of 3489 patients with lupus erythematosus were followed for 23 373 person-years. Compared with the general population, the adjusted hazard ratios (HRs) of depression were 2·07 [95% confidence interval (CI) 1·55-2·75] and 2·22 (95% CI 1·77-2·77) for patients with CLE and SLE, respectively; for hospitalization owing to depression at a department of psychiatry HRs were 2·63 (95% CI 0·80-8·67) and 3·52 (95% CI 1·53-8·11) for patients with CLE and SLE, respectively. The adjusted HRs for antidepressant use were 1·47 (95% CI 1·34-1·63) and 1·70 (95% CI 1·58-1·83) for patients with CLE and SLE, respectively. CONCLUSIONS: The risk of depression was significantly increased in patients with SLE and CLE. Awareness of an increased risk of depression in patients with SLE and CLE might be warranted.
BACKGROUND: There is a wide range in the reported prevalences of depression in patients with systemic lupus erythematosus (SLE), while the prevalence of depression in patients with cutaneous lupus erythematosus (CLE) remains severely understudied. OBJECTIVES: To examine whether patients with SLE or CLE have an increased risk of depression. METHODS: In this nationwide observational cohort study, we included patients aged ≥ 18 years with a first-time diagnosis of SLE or CLE between 2000 and 2015 identified in the Danish National Patient Register, which were matched with the general population in a ratio of 1 : 10. After linkage to national Danish health registers of primary and secondary care, analyses of risk for depression and antidepressant use were performed using Cox regression models adjusted for age, sex, socioeconomic status, smoking, alcohol abuse, prior depression and prior antidepressant use. RESULTS: A total of 3489 patients with lupus erythematosus were followed for 23 373 person-years. Compared with the general population, the adjusted hazard ratios (HRs) of depression were 2·07 [95% confidence interval (CI) 1·55-2·75] and 2·22 (95% CI 1·77-2·77) for patients with CLE and SLE, respectively; for hospitalization owing to depression at a department of psychiatry HRs were 2·63 (95% CI 0·80-8·67) and 3·52 (95% CI 1·53-8·11) for patients with CLE and SLE, respectively. The adjusted HRs for antidepressant use were 1·47 (95% CI 1·34-1·63) and 1·70 (95% CI 1·58-1·83) for patients with CLE and SLE, respectively. CONCLUSIONS: The risk of depression was significantly increased in patients with SLE and CLE. Awareness of an increased risk of depression in patients with SLE and CLE might be warranted.
Authors: Jennifer Hong; Laura Aspey; Gaobin Bao; Tamara Haynes; S Sam Lim; Cristina Drenkard Journal: Am J Clin Dermatol Date: 2019-06 Impact factor: 7.403
Authors: John Abel Engh; Thor Ueland; Ingrid Agartz; Dimitrios Andreou; Pål Aukrust; Birgitte Boye; Erlend Bøen; Ole Kristian Drange; Torbjørn Elvsåshagen; Sigrun Hope; Margrethe Collier Høegh; Inge Joa; Erik Johnsen; Rune Andreas Kroken; Trine Vik Lagerberg; Tove Lekva; Ulrik Fredrik Malt; Ingrid Melle; Gunnar Morken; Terje Nærland; Vidar Martin Steen; Kirsten Wedervang-Resell; Melissa Auten Weibell; Lars Tjelta Westlye; Srdjan Djurovic; Nils Eiel Steen; Ole Andreas Andreassen Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 7.348
Authors: Cristina Drenkard; Kristina A Theis; Timothy T Daugherty; Charles G Helmick; Charmayne Dunlop-Thomas; Gaobin Bao; Laura Aspey; Tené T Lewis; S Sam Lim Journal: Lupus Sci Med Date: 2022-08